Targeting epidermal growth factor receptor--are we missing the mark? (Q35174501)

6 August 2017

1 reference

title

Targeting epidermal growth factor receptor--are we missing the mark? (English)

1 reference

6 August 2017

2

Boris Freidlin

1 reference

6 August 2017

Janet E Dancey

1

1 reference

PubMed ID

12853203

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

6 August 2017

1 reference

6 August 2017

362

1 reference

6 August 2017

62-64

1 reference

6 August 2017

9377

1 reference

Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913810-X

7 January 2021

Severe acute interstitial pneumonia and gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913810-X

7 January 2021

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913810-X

7 January 2021

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913810-X

7 January 2021

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913810-X

7 January 2021

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913810-X

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913810-X

7 January 2021

Influence of unrecognized molecular heterogeneity on randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913810-X

7 January 2021

10.1016/S0140-6736(03)13810-X

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12853203